{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:51:18Z","timestamp":1781848278471,"version":"3.54.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:00:00Z","timestamp":1777766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The First Affiliated Hospital of Nanjing Medical University","award":["2025BSH041"],"award-info":[{"award-number":["2025BSH041"]}]},{"name":"Xuzhou Health Commission","award":["2018TD005"],"award-info":[{"award-number":["2018TD005"]}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"crossref","award":["Y-SYBLD2022RWR-0013"],"award-info":[{"award-number":["Y-SYBLD2022RWR-0013"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"crossref","award":["BK20232039"],"award-info":[{"award-number":["BK20232039"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470186"],"award-info":[{"award-number":["82470186"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05153-3","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T08:53:12Z","timestamp":1777798392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A lipid nanoparticle-based peptide-proteolysis-targeting chimera degrades BCL6 for diffuse large B-cell lymphoma treatment"],"prefix":"10.1007","volume":"17","author":[{"given":"Shiwei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangsui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haorui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,3]]},"reference":[{"issue":"5134","key":"5153_CR1","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1126\/science.8235596","volume":"262","author":"BH Ye","year":"1993","unstructured":"Ye BH, Lista F, Lo Coco F, Knowles DM, Offit K, Chaganti RS, et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science. 1993;262(5134):747\u201350.","journal-title":"Science"},{"issue":"12","key":"5153_CR2","first-page":"2732","volume":"53","author":"BH Ye","year":"1993","unstructured":"Ye BH, Rao PH, Chaganti RS, Dalla-Favera R. Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma. Cancer Res. 1993;53(12):2732\u20135.","journal-title":"Cancer Res"},{"issue":"3","key":"5153_CR3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ccr.2007.08.011","volume":"12","author":"M Saito","year":"2007","unstructured":"Saito M, Gao J, Basso K, Kitagawa Y, Smith PM, Bhagat G, et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell. 2007;12(3):280\u201392.","journal-title":"Cancer Cell"},{"issue":"7379","key":"5153_CR4","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nature10688","volume":"481","author":"S Duan","year":"2012","unstructured":"Duan S, Cermak L, Pagan JK, Rossi M, Martinengo C, di Celle PF, et al. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature. 2012;481(7379):90\u20133.","journal-title":"Nature"},{"issue":"6","key":"5153_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.molmed.2014.03.001","volume":"20","author":"K Hatzi","year":"2014","unstructured":"Hatzi K, Melnick A. Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. Trends Mol Med. 2014;20(6):343\u201352.","journal-title":"Trends Mol Med"},{"issue":"22","key":"5153_CR6","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1182\/blood-2008-12-193037","volume":"113","author":"W Ci","year":"2009","unstructured":"Ci W, Polo JM, Cerchietti L, Shaknovich R, Wang L, Yang SN, et al. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood. 2009;113(22):5536\u201348.","journal-title":"Blood"},{"issue":"7017","key":"5153_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nature03147","volume":"432","author":"RT Phan","year":"2004","unstructured":"Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature. 2004;432(7017):635\u20139.","journal-title":"Nature"},{"issue":"5","key":"5153_CR8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ccr.2005.03.037","volume":"7","author":"G Cattoretti","year":"2005","unstructured":"Cattoretti G, Pasqualucci L, Ballon G, Tam W, Nandula SV, Shen Q, et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell. 2005;7(5):445\u201355.","journal-title":"Cancer Cell"},{"issue":"39","key":"5153_CR9","doi-asserted-by":"publisher","first-page":"14198","DOI":"10.1073\/pnas.0406138101","volume":"101","author":"BW Baron","year":"2004","unstructured":"Baron BW, Anastasi J, Montag A, Huo D, Baron RM, Karrison T, et al. The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc Natl Acad Sci U S A. 2004;101(39):14198\u2013203.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"5153_CR10","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1158\/1541-7786.MCR-22-0567","volume":"20","author":"T McLachlan","year":"2022","unstructured":"McLachlan T, Matthews WC, Jackson ER, Staudt DE, Douglas AM, Findlay IJ, et al. B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers. Mol Cancer Res. 2022;20(12):1711\u201323.","journal-title":"Mol Cancer Res"},{"issue":"6","key":"5153_CR11","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood.2019001745","volume":"137","author":"KC Kawabata","year":"2021","unstructured":"Kawabata KC, Zong H, Meydan C, Wyman S, Wouters BJ, Sugita M, et al. BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells. Blood. 2021;137(6):812\u201325.","journal-title":"Blood"},{"issue":"11","key":"5153_CR12","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1084\/jem.20110304","volume":"208","author":"C Hurtz","year":"2011","unstructured":"Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med. 2011;208(11):2163\u201374.","journal-title":"J Exp Med"},{"key":"5153_CR13","doi-asserted-by":"publisher","first-page":"113473","DOI":"10.1016\/j.ejmech.2021.113473","volume":"220","author":"X Liang","year":"2021","unstructured":"Liang X, Wu P, Yang Q, Xie Y, He C, Yin L, et al. An update of new small-molecule anticancer drugs approved from 2015 to 2020. Eur J Med Chem. 2021;220:113473.","journal-title":"Eur J Med Chem"},{"issue":"1","key":"5153_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.5582\/ddt.2021.01013","volume":"15","author":"J Li","year":"2021","unstructured":"Li J, Wang R, Gao J. Novel anticancer drugs approved in 2020. Drug Discov Ther. 2021;15(1):44\u20137.","journal-title":"Drug Discov Ther"},{"issue":"4","key":"5153_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","volume":"20","author":"D Chirnomas","year":"2023","unstructured":"Chirnomas D, Hornberger KR, Crews CM. Protein degraders enter the clinic - a new approach to cancer therapy. Nat Rev Clin Oncol. 2023;20(4):265\u201378.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"5153_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","volume":"13","author":"X Li","year":"2020","unstructured":"Li X, Song Y. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. J Hematol Oncol. 2020;13(1):50.","journal-title":"J Hematol Oncol"},{"key":"5153_CR17","doi-asserted-by":"crossref","unstructured":"Peng Y, Liu D, Huang D, Inuzuka H, Liu J. PROTAC as a novel anti-cancer strategy by targeting aging-related signaling. Semin Cancer Biol. 2024;106\u20137:143\u201355.","DOI":"10.1016\/j.semcancer.2024.09.004"},{"issue":"1","key":"5153_CR18","doi-asserted-by":"publisher","first-page":"103395","DOI":"10.1016\/j.drudis.2022.103395","volume":"28","author":"N Guedeney","year":"2023","unstructured":"Guedeney N, Cornu M, Schwalen F, Kieffer C, Voisin-Chiret AS. PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery. Drug Discov Today. 2023;28(1):103395.","journal-title":"Drug Discov Today"},{"key":"5153_CR19","doi-asserted-by":"crossref","unstructured":"Wang L, Xiao Y, Luo Y, Master RP, Mo J, Kim MC et al. PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. J Exp Med. 2024;221(3).","DOI":"10.1084\/jem.20231519"},{"issue":"3","key":"5153_CR20","doi-asserted-by":"publisher","first-page":"e2411454","DOI":"10.1002\/adma.202411454","volume":"37","author":"Y Yao","year":"2025","unstructured":"Yao Y, Wu M, Wang Y, Liao Z, Yang Y, Liu Y, et al. An Oral PROTAC Targeting HPK1 Degradation Potentiates Anti-Solid Tumor Immunity. Adv Mater. 2025;37(3):e2411454.","journal-title":"Adv Mater"},{"key":"5153_CR21","doi-asserted-by":"publisher","first-page":"116154","DOI":"10.1016\/j.ejmech.2024.116154","volume":"267","author":"J Velez","year":"2024","unstructured":"Velez J, Dale B, Park KS, Kaniskan H, Yu X, Jin J. Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2. Eur J Med Chem. 2024;267:116154.","journal-title":"Eur J Med Chem"},{"issue":"17","key":"5153_CR22","doi-asserted-by":"publisher","first-page":"11269","DOI":"10.1021\/acs.chemrev.7b00077","volume":"117","author":"GM Burslem","year":"2017","unstructured":"Burslem GM, Crews CM. Small-Molecule Modulation of Protein Homeostasis. Chem Rev. 2017;117(17):11269\u2013301.","journal-title":"Chem Rev"},{"issue":"11","key":"5153_CR23","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1021\/acscentsci.4c01385","volume":"10","author":"B Xue","year":"2024","unstructured":"Xue B, Li R, Cheng Z, Zhou X. High-Affinity Peptides for Target Protein Screened in Ultralarge Virtual Libraries. ACS Cent Sci. 2024;10(11):2111\u20138.","journal-title":"ACS Cent Sci"},{"key":"5153_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1146\/annurev-pharmtox-010715-103440","volume":"56","author":"JS Lazo","year":"2016","unstructured":"Lazo JS, Sharlow ER. Drugging Undruggable Molecular Cancer Targets. Annu Rev Pharmacol Toxicol. 2016;56:23\u201340.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"5153_CR25","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13046-022-02483-2","volume":"41","author":"K Wang","year":"2022","unstructured":"Wang K, Dai X, Yu A, Feng C, Liu K, Huang L. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression. J Exp Clin Cancer Res. 2022;41(1):289.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"5153_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13062-024-00580-0","volume":"19","author":"S Liu","year":"2024","unstructured":"Liu S, Yuan F, Dong H, Zhang J, Mao X, Liu Y, et al. PTGES3 proteolysis using the liposomal peptide-PROTAC approach. Biol Direct. 2024;19(1):144.","journal-title":"Biol Direct"},{"issue":"18","key":"5153_CR27","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1158\/0008-5472.CAN-24-4096","volume":"85","author":"Q Ye","year":"2025","unstructured":"Ye Q, Ma B, Li L, Wang Z, Lu M, Kang J, et al. A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition. Cancer Res. 2025;85(18):3490\u2013502.","journal-title":"Cancer Res"},{"issue":"22","key":"5153_CR28","doi-asserted-by":"publisher","first-page":"10141","DOI":"10.7150\/thno.46985","volume":"10","author":"J Jin","year":"2020","unstructured":"Jin J, Wu Y, Chen J, Shen Y, Zhang L, Zhang H, et al. The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination. Theranostics. 2020;10(22):10141\u201353.","journal-title":"Theranostics"},{"issue":"12","key":"5153_CR29","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.1039\/D0BM01947J","volume":"9","author":"M Herrera","year":"2021","unstructured":"Herrera M, Kim J, Eygeris Y, Jozic A, Sahay G. Illuminating endosomal escape of polymorphic lipid nanoparticles that boost mRNA delivery. Biomater Sci. 2021;9(12):4289\u2013300.","journal-title":"Biomater Sci"},{"issue":"3","key":"5153_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21(3):181\u2013200.","journal-title":"Nat Rev Drug Discov"},{"key":"5153_CR31","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ebiom.2018.09.005","volume":"36","author":"S An","year":"2018","unstructured":"An S, Fu L. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018;36:553\u201362.","journal-title":"EBioMedicine"},{"key":"5153_CR32","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ejmech.2015.01.014","volume":"94","author":"N Tsomaia","year":"2015","unstructured":"Tsomaia N. Peptide therapeutics: targeting the undruggable space. Eur J Med Chem. 2015;94:459\u201370.","journal-title":"Eur J Med Chem"},{"issue":"2","key":"5153_CR33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.bbrc.2016.11.060","volume":"482","author":"K Sakamoto","year":"2017","unstructured":"Sakamoto K, Sogabe S, Kamada Y, Sakai N, Asano K, Yoshimatsu M, et al. Discovery of high-affinity BCL6-binding peptide and its structure-activity relationship. Biochem Biophys Res Commun. 2017;482(2):310\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"5153_CR34","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/nprot.2014.138","volume":"9","author":"R Jafari","year":"2014","unstructured":"Jafari R, Almqvist H, Axelsson H, Ignatushchenko M, Lundb\u00e4ck T, Nordlund P, et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat Protoc. 2014;9(9):2100\u201322.","journal-title":"Nat Protoc"},{"issue":"9","key":"5153_CR35","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1021\/acsmedchemlett.0c00265","volume":"11","author":"VG Klein","year":"2020","unstructured":"Klein VG, Townsend CE, Testa A, Zengerle M, Maniaci C, Hughes SJ, et al. Understanding and Improving the Membrane Permeability of VH032-Based PROTACs. ACS Med Chem Lett. 2020;11(9):1732\u20138.","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"5153_CR36","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12951-022-01478-7","volume":"20","author":"SH Kiaie","year":"2022","unstructured":"Kiaie SH, Majidi Zolbanin N, Ahmadi A, Bagherifar R, Valizadeh H, Kashanchi F, et al. Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects. J Nanobiotechnol. 2022;20(1):276.","journal-title":"J Nanobiotechnol"},{"issue":"Pt A","key":"5153_CR37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.addr.2016.01.022","volume":"99","author":"X Cheng","year":"2016","unstructured":"Cheng X, Lee RJ. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev. 2016;99(Pt A):129\u201337.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1\u20132","key":"5153_CR38","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.bbamem.2004.03.004","volume":"1663","author":"Y Zhang","year":"2004","unstructured":"Zhang Y, Anchordoquy TJ. The role of lipid charge density in the serum stability of cationic lipid\/DNA complexes. Biochim Biophys Acta. 2004;1663(1\u20132):143\u201357.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"5153_CR39","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1158\/1078-0432.CCR-16-2071","volume":"23","author":"MG Cardenas","year":"2017","unstructured":"Cardenas MG, Oswald E, Yu W, Xue F, MacKerell AD Jr., Melnick AM. The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target. Clin Cancer Res. 2017;23(4):885\u201393.","journal-title":"Clin Cancer Res"},{"key":"5153_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/jpm11080771","volume":"11","author":"J Wu","year":"2021","unstructured":"Wu J. The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application. J Pers Med. 2021;11:8.","journal-title":"J Pers Med"},{"key":"5153_CR41","doi-asserted-by":"publisher","first-page":"102915","DOI":"10.1016\/j.pdpdt.2022.102915","volume":"39","author":"VR Shinde","year":"2022","unstructured":"Shinde VR, Revi N, Murugappan S, Singh SP, Rengan AK. Enhanced permeability and retention effect: A key facilitator for solid tumor targeting by nanoparticles. Photodiagnosis Photodyn Ther. 2022;39:102915.","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"Pt 3","key":"5153_CR42","doi-asserted-by":"publisher","first-page":"142667","DOI":"10.1016\/j.ijbiomac.2025.142667","volume":"308","author":"S Zhao","year":"2025","unstructured":"Zhao S, Luo J, Xu P, Zeng J, Yan G, Yu F, et al. Designed peptide binders and nanobodies as PROTAC starting points for targeted degradation of PCNA and BCL6. Int J Biol Macromol. 2025;308(Pt 3):142667.","journal-title":"Int J Biol Macromol"},{"issue":"19","key":"5153_CR43","doi-asserted-by":"publisher","first-page":"20180","DOI":"10.1021\/acs.jmedchem.5c01237","volume":"68","author":"X Yu","year":"2025","unstructured":"Yu X, Liao X, Zhang J, Wang H, Li X, Lu J, et al. Discovery of a Selective and Potent BCL6 PROTAC with Efficacious Antiproliferative Activity for the Treatment of Diffuse Large B-Cell Lymphoma. J Med Chem. 2025;68(19):20180\u2013206.","journal-title":"J Med Chem"},{"key":"5153_CR44","doi-asserted-by":"publisher","first-page":"116789","DOI":"10.1016\/j.ejmech.2024.116789","volume":"277","author":"D Mi","year":"2024","unstructured":"Mi D, Li C, Li Y, Yao M, Li Y, Hong K, et al. Discovery of novel BCL6-Targeting PROTACs with effective antitumor activities against DLBCL in vitro and in vivo. Eur J Med Chem. 2024;277:116789.","journal-title":"Eur J Med Chem"},{"issue":"11","key":"5153_CR45","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1021\/acschembio.8b00698","volume":"13","author":"W McCoull","year":"2018","unstructured":"McCoull W, Cheung T, Anderson E, Barton P, Burgess J, Byth K, et al. Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6. ACS Chem Biol. 2018;13(11):3131\u201341.","journal-title":"ACS Chem Biol"},{"key":"5153_CR46","doi-asserted-by":"crossref","unstructured":"Moon Y, Jeon SI, Shim MK, Kim K. Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy. Pharmaceutics. 2023;15(2).","DOI":"10.3390\/pharmaceutics15020411"},{"key":"5153_CR47","doi-asserted-by":"crossref","unstructured":"Soundararajan A, Bao A, Phillips WT, Perez R 3rd, Goins BA. [(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. Nucl Med Biol. 2009;36(5):515\u201324.","DOI":"10.1016\/j.nucmedbio.2009.02.004"},{"key":"5153_CR48","doi-asserted-by":"publisher","first-page":"101512","DOI":"10.1016\/j.nantod.2022.101512","volume":"45","author":"S Wang","year":"2022","unstructured":"Wang S, Cheng K, Chen K, Xu C, Ma P, Dang G, et al. Nanoparticle-based medicines in clinical cancer therapy. Nano Today. 2022;45:101512.","journal-title":"Nano Today"},{"issue":"1","key":"5153_CR49","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.nano.2005.12.003","volume":"2","author":"CP Reis","year":"2006","unstructured":"Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F, Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine. 2006;2(1):8\u201321.","journal-title":"Nanomedicine"},{"issue":"10","key":"5153_CR50","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.tips.2020.08.008","volume":"41","author":"T Minko","year":"2020","unstructured":"Minko T. Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the \u2018Undruggable\u2019 MYC in Pancreatic Cancer. Trends Pharmacol Sci. 2020;41(10):684\u20136.","journal-title":"Trends Pharmacol Sci"},{"key":"5153_CR51","doi-asserted-by":"crossref","unstructured":"Fu Y, Saraswat A, Wei Z, Agrawal MY, Dukhande VV, Reznik SE et al. Development of Dual ARV-825 and Nintedanib-Loaded PEGylated Nano-Liposomes for Synergistic Efficacy in Vemurafnib-Resistant Melanoma. Pharmaceutics. 2021;13(7).","DOI":"10.3390\/pharmaceutics13071005"},{"issue":"1","key":"5153_CR52","doi-asserted-by":"publisher","first-page":"e08702","DOI":"10.1016\/j.heliyon.2021.e08702","volume":"8","author":"A Saraswat","year":"2022","unstructured":"Saraswat A, Vemana HP, Dukhande VV, Patel K. Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy. Heliyon. 2022;8(1):e08702.","journal-title":"Heliyon"},{"issue":"3","key":"5153_CR53","first-page":"1027","volume":"12","author":"R Fan","year":"2022","unstructured":"Fan R, He S, Wang Y, Qiao J, Liu H, Galstyan L, et al. Targeted delivery of a PROTAC induced PDE\u03b4 degrader by a biomimetic drug delivery system for enhanced cytotoxicity against pancreatic cancer cells. Am J Cancer Res. 2022;12(3):1027\u201341.","journal-title":"Am J Cancer Res"},{"key":"5153_CR54","doi-asserted-by":"publisher","first-page":"110795","DOI":"10.1016\/j.colsurfb.2020.110795","volume":"188","author":"Y Wang","year":"2020","unstructured":"Wang Y, Han L, Liu F, Yang F, Jiang X, Sun H, et al. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras. Colloids Surf B Biointerfaces. 2020;188:110795.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"5153_CR55","doi-asserted-by":"crossref","unstructured":"Mortensen DS, Shunatona HP, Holmberg-Douglas N, Rhodes J, Da Silva D, Gamez J et al. Discovery of BMS-986458, a Potent and Selective B-Cell Lymphoma 6 Protein Ligand-Directed Degrader, for the Treatment of B-Cell Non-Hodgkin Lymphoma. J Med Chem. 2026.","DOI":"10.1021\/acs.jmedchem.5c03123"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05153-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05153-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05153-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:03:06Z","timestamp":1781845386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05153-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,3]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5153"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05153-3","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,3]]},"assertion":[{"value":"6 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BALB\/c nude mice (GemPharmatech Co., Ltd, China) were housed in a specific pathogen-free environment of Nanjing Medical University (Nanjing, China). All operations involving live mice were conducted in accordance with established ethical guidelines of the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The present study has been approved by the Animal Core Facility of Nanjing Medical University (approval numbers IACUC-2509074). The maximal tumor size permitted by our institutional ethics committee guidelines is 20\u00a0mm in diameter. We confirm that the maximal tumor size\/burden as outlined by our ethics committee was not exceeded at any point during the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"929"}}